HCWB - Investigator Sponsor Presents Human Data Readout from HCW Biologics' Phase 1 Clinical Trial of HCW9218 at 38th SITC Annual Meeting

2023-11-08 09:40:13 ET

DENVER, Colo., Nov 8, 2023 ( www.247marketnews.com )- HCW Biologics Inc (NASDAQ: HCWB) stated that data from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, was presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”).

HCW Biologics is trading at $1.73, up $0.13 (+8.12%) on 272K premarket shares.

Its 52-week range is $1.08 to $2.35. This morning’s premarket volume is way larger than its typical daily volume, so this could make a nice run today.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock …

The post Investigator Sponsor Presents Human Data Readout from HCW Biologics’ Phase 1 Clinical Trial of HCW9218 at 38th SITC Annual Meeting appeared first on 24/7 Market News .

For further details see: